Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy -: A status report

被引:55
作者
Balfour, D
Benowitz, N
Fagerström, K
Kunze, M
Keil, U
机构
[1] Univ Munster, Inst Epidemiol & Social Med, Fac Med, D-48129 Munster, Germany
[2] Univ Dundee, Sch Med, Dept Pharmacol & Neurosci, Dundee, Scotland
[3] Univ Calif San Francisco, San Francisco Gen Hosp, Clin Pharmacol Unit, Med Serv, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Pharm, San Francisco, CA USA
[7] Fagerstrom Consulting, S-25225 Helsingborg, Sweden
[8] Univ Vienna, Inst Social Med, Vienna, Austria
关键词
tobacco dependence; smoking cessation; nicotine replacement therapy;
D O I
10.1053/euhj.1999.1949
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tobacco use is a global health care problem. Repetitive exposure to nicotine produces neuroadaptation resulting in nicotine dependence. Cigarette smoking is particularly addictive due to the repeated delivery of bolus doses of nicotine to the bloodstream. Although compulsive tobacco use is sustained by nicotine addiction, it is the toxic combustion products in tobacco smoke such as carbon monoxide and oxidant gases that adversely affect the cardiovascular system. Smoking cessation produces significant health benefits and is a very cost-effective intervention. Evidence that nicotine is the addictive component of tobacco provides the rationale for using nicotine replacement therapy to aid cessation. Nicotine replacement therapy doubles successful smoking cessation fates and evidence-based guidelines for the treatment of tobacco addiction recommend routine use of nicotine replacement therapy, particularly in heavily dependent smokers. Success rates of up to 40% can be achieved in specialist clinics. Despite early concerns regarding the safety of nicotine replacement therapy in smokers with heart disease, it is now clear that the health risks of using nicotine replacement therapy to assist such patients to stop, or significantly reduce, smoking far outweigh any treatment-related risks. (C) 2000 The European Society of Cardiology.
引用
收藏
页码:438 / 445
页数:8
相关论文
共 50 条
[21]   MEASURING NICOTINE DEPENDENCE - A REVIEW OF THE FAGERSTROM TOLERANCE QUESTIONNAIRE [J].
FAGERSTROM, KO ;
SCHNEIDER, NG .
JOURNAL OF BEHAVIORAL MEDICINE, 1989, 12 (02) :159-182
[22]   EFFECTIVENESS OF NICOTINE PATCH AND NICOTINE GUM AS INDIVIDUAL VERSUS COMBINED TREATMENTS FOR TOBACCO WITHDRAWAL SYMPTOMS [J].
FAGERSTROM, KO ;
SCHNEIDER, NG ;
LUNELL, E .
PSYCHOPHARMACOLOGY, 1993, 111 (03) :271-277
[23]  
GRAEFF FG, 1996, PHARM BIOCH BEHAV, V5, P305
[24]  
HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
[25]   Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome [J].
Hildebrand, BE ;
Nomikos, GG ;
Hertel, P ;
Schilström, B ;
Svensson, TH .
BRAIN RESEARCH, 1998, 779 (1-2) :214-225
[26]   Nicotine replacement: a new approach to reducing tobacco-related harm [J].
Jimenez-Ruiz, C ;
Kunze, M ;
Fagerstrom, KO .
EUROPEAN RESPIRATORY JOURNAL, 1998, 11 (02) :473-479
[27]  
Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903
[28]   The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease [J].
Joseph, AM ;
Norman, SM ;
Ferry, LH ;
Prochazka, AV ;
Westman, EC ;
Steele, BG ;
Sherman, SE ;
Cleveland, M ;
Antonnucio, DO ;
Hartman, N ;
McGovern, PG .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (24) :1792-1798
[29]  
KALIVAS PW, 1993, BEHAV PHARMACOL, V4, P315
[30]   Smoking cessation: EMASH consensus [J].
Kunze, U ;
Schmeiser-Rieder, A ;
Schoberberger, R .
SOZIAL-UND PRAVENTIVMEDIZIN, 1998, 43 (03) :167-172